Last €0.19 EUR
Change Today 0.00 / 0.00%
Volume 0.0
IC9A On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 4:00 PM 10/30/13 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (IC9A) Snapshot

Open
--
Previous Close
€0.19
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
134.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEOLUS PHARMACEUTICALS INC (IC9A)

Related News

No related news articles were found.

aeolus pharmaceuticals inc (IC9A) Related Businessweek News

No Related Businessweek News Found

aeolus pharmaceuticals inc (IC9A) Details

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the development of a platform of novel compounds in biodefense and oncology. The company develops a class of catalytic antioxidant compounds as medical countermeasures against biological, chemical, and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Its lead compound, AEOL 10150, which has completed 2 Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as for the gastrointestinal sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas, phosgene gas, and nerve agents. The company is also developing AEOL 11207, AEOL 10113, and AEOL 10171 for the treatment of epilepsy and Parkinson’s disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

4 Employees
Last Reported Date: 06/2/14
Founded in 1994

aeolus pharmaceuticals inc (IC9A) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $421.3K
Chairman of The Board, Chief Financial Office...
Total Annual Compensation: $342.3K
Compensation as of Fiscal Year 2013.

aeolus pharmaceuticals inc (IC9A) Key Developments

Aeolus Pharmaceuticals, Inc. Announces Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure

Aeolus Pharmaceuticals Inc. announced the publication of data from animal model studies demonstrating the efficacy of AEOL 10150 when used to treat skin lesions from the sulfur mustard gas analog CEES. The key findings described in the publication include: Treatment of mice with AEOL 10150 resulted in over 50%(p < 0.05) reversal of CEES-induced skin bi-fold and epidermal thickness, myeloperoxidase activity, and DNA oxidation in mouse skin; Treatment of mouse epidermal JB6 and human HaCaT cells with AEOL 10150 (50 uM) 1 hour post-CEES exposure resulted in significant (p < 0.05) reversal of CEES-induced decreases in both cell viability and DNA synthesis; AEOL 10150 treatment 1 hour after CEES exposure attenuated CEES-induced DNA damage in mouse epidermal JB6 and human HaCaT cells; Cytoplasmic and mitochondrial reactive oxygen species measurements showed that AEOL 10150 treatment drastically ameliorated the CEES-induced oxidative stress in both JB6 and HaCaT cells.

Aeolus Pharmaceuticals Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 04:30 PM

Aeolus Pharmaceuticals Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 04:30 PM. Venue: Luxe Sunset Bel Air, 11461 Sunset Boulevard, Los Angeles, CA 90049, United States. Speakers: David C. Cavalier, Chairman of The Board, Chief Financial Officer, Principal Accounting Officer and Secretary.

Aeolus Pharmaceuticals Inc., Q2 2014 Earnings Call, May 19, 2014

Aeolus Pharmaceuticals Inc., Q2 2014 Earnings Call, May 19, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IC9A:GR €0.19 EUR 0.00

IC9A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IC9A.
View Industry Companies
 

Industry Analysis

IC9A

Industry Average

Valuation IC9A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.3x
Price/Book 1,160.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit www.aeoluspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.